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Multi-layered tabletsAbstract The rapid availability of the drug at the site of action followed by maintaining its effect
for a long period of time is of great clinical importance. Thus, the purpose of the present study was
to prepare and evaluate multi-layered matrix tablets of diclofenac using Eudragit RL/RS blend to
achieve both immediate and sustained therapeutic effects. Diclofenac potassium (25 mg) was incor-
porated in an outer immediate release layer to provide immediate pain relief whereas diclofenac
sodium (75 mg) was incorporated in the inner core to provide extended drug release. Wet granula-
tion was employed to prepare the inner core of the tablets that were further layered with an imme-
diate release drug layer in the perforated pan coater. The in-vitro and in-vivo performance of the
developed formulation was compared with the marketed products Voltaren SR 75 mg and Cata-
flam 25 mg. The in-vitro drug release of the prepared formulation showed similarity (f2 = 66.19)
to the marketed product. The pharmacokinetic study showed no significant difference (p> 0.05) in
AUC0-24 and Cmax between the test and reference formulations. The AUC0-24 values were 105.36
± 83.3 and 92.87 ± 55.53 lg h/ml whereas the Cmax values were 11.25 ± 6.87 and 12.97
± 8.45 lg/ml, for the test and reference, respectively. The multi-layered tablets were proved to
be bioequivalent with the commercially available tablets and were in agreement with the observeddi Phar-
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maceutical Journal (2016), http://dx.doi.org/in-vitro drug release results. Stable physical characteristics and drug release profiles were observed
in both long term and accelerated conditions stability studies.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
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Diclofenac Sodium (DS) (sodium;2-[2-(2,6-dichloroanilino)
phenyl]acetate) is a potent non-steroidal anti-inflammatory
drug (NSAID) and one of the most useful pain killers, used
clinically in treatment of rheumatic or non-rheumatic inflam-
matory diseases. Diclofenac inhibits the conversion of arachi-
donic acid to prostaglandins which are responsible for the
inflammatory process (Fini et al., 2007; Kovala-Demertzi,
2006).
The extended release (ER) tablets containing 75 mg of
diclofenac sodium are administered as once daily to guarantee
less frequent dosing and diminished occurrence of gastro-
intestinal side effects (Shaw et al., 2005). Different release
matrices have been proposed for the preparation of diclofenac
ER formulations (Gonza´lez-Rodrı ´Guez et al., 2003; Su et al.,
2003) using different polymers including HPMC with various
grades (Moura˜o et al., 2010) and Eudragits (Gonza´lez-Rodrı ´
Guez et al., 2003; Pignatello et al., 2002). In most therapies,
such ER preparations are desirable. However, in certain cases,
rapid availability of the drug as a loading dose is needed to
relieve the symptoms of the disease, followed by a maintenance
dose of an effective drug plasma level for the continuation of
the clinical effects. The combination of different drug delivery
forms (immediate, enteric or sustained) of diclofenac in one
pharmaceutical formulation has been explored (Lim et al.,
2012; Sawayanagi and Otani, 1990; Shaw, 2012). Marketed
pharmaceutical products, namely Diclofenac Duo 75 mg
(PharmaSwiss) or Divido 75 mg (Tabuk Pharmaceuticals),
contain two drug delivery forms of the drug (25 mg diclofenac
sodium in gastro-resistant form and 50 mg diclofenac sodium
in prolonged-release form) in each hard gelatin capsule. Fast
release of the drug from such formulations is not substantial.
Release of the drug from the prolonged release form may start
in the stomach but the amount released is not adequate to
achieve a rapid pharmacologic response because of the low
acidic solubility of DS. In addition, the lag time associated
with the gastro-resistant form of the drug will contribute to
the delayed response. Such preparations are not suitable for
initiating treatment of conditions where rapid onset of action
is needed. Accordingly, in this study, development of multi-
layered tablet that combines two drug delivery forms (immedi-
ate and sustained) using two salt forms of diclofenac was pur-
sued. Diclofenac potassium (DP), with a relatively higher
water solubility and faster dissolution and absorption rate
than observed with the sodium salt (Ahmad et al., 2010;
Altman et al., 2015), was used to achieve prompt pain relief
by incorporating it into an immediate release, fast dissolving
outer layer, whereas the sodium salt with its lower solubility
was incorporated into an insoluble matrix inner core to be
released slowly and provide a sustained analgesic effect. This
kind of formulation is expected to add a clinical and therapeu-
tic value, especially for patients taking multiple drugs. The
multi-layered tablets were prepared and assessed for their in-. et al., Formulation and pharmacokin
10.1016/j.jsps.2016.10.004vitro behavior, in-vivo performance and stability in this
research.
2. Materials and methods
2.1. Materials
DS and DP were kindly supplied by TABUK Pharmaceuticals
(Tabuk, Saudi Arabia). Eudragit RL PO and Eudragit RS PO
were obtained from Evonik (Germany). Granulac 200 (lac-
tose monohydrate) was kindly supplied by Meggle Pharma
(Wassenberg, Germany). Vivapur PH 101 (microcrystalline
cellulose or MCC) was purchased from JRS Pharma (Weis-
senborn, Germany). All other chemicals were of pharmaceuti-
cal grade.2.2. Methods
2.2.1. Preparation of the inner core matrix tablets
A high shear mixer was used to prepare tablets by a wet-
granulation technique. In our previous work (Elzayat et al.,
2016b), the polymer concentration and compression force were
optimized using a two factor, three level (32) full factorial
design to obtain tablets matching the release profile of Volta-
ren SR 75 mg and at the same time matching USP acceptance
criteria for extended release diclofenac tablets. Briefly, each
tablet of the optimized formulation (designated as Formula-
tion E) contains 75 mg of DS, 52.5 mg of a 1:1 w/w blend of
Eudragit RL and Eudragit RS, 3.5 mg of magnesium stearate,
1.75 mg of colloidal silicon dioxide and a sufficient quantity of
a 70:30 w/w filler blend consisting of a mixture of lactose
monohydrate and MCC to achieve a final tablet weight of
350 mg. Each 600 g of the powder blend specified in the exper-
imental design was sieved through a 0.63 mm mesh screen and
then mixed in the high shear mixer (chopper speed = 700 rpm,
impeller speed = 200 rpm) for 20 min. A 20% w/v ethanolic
solution of a 1:1 w/w mixture of Eudragit RL and Eudragit
RS was used for granulation of the powder blend in the high
shear mixer with the chopper speed at 2500 rpm, the impeller
speed at 200 rpm, the spray rate at 46 ml/min, and the wet
massing time set at 5 min to obtain the desired mass consis-
tency. The amount of the polymer in the granulating solution
was subtracted from the total amount of the polymer assigned
for the formulation. The wetted mass was sieved through a
1.25 mm aperture mesh. Drying of the granules was carried
out in a hot air oven (Memmert, Tv80ul, Germany) for 1 h
at 40 C. The percent of the residual solvent, 2–3% was calcu-
lated using an infrared dryer (Mettler, LP16 Greifensee,
Switzerland). The dried granules were passed through a
0.8 mm mesh screen. A mixture of 1% w/w magnesium stea-
rate and 0.5% w/w colloidal silicon dioxide was added and
mixed in the high shear mixer (chopper speed = 400 rpm,
impeller speed = 200 rpm for 5 min). The tablets were com-etics of multi-layered matrix tablets: Biphasic delivery of diclofenac. Saudi Phar-
Table 1 Study design of the crossover bioequivalence study.
Sequence Dogs Treatment
Period 1 Period 2
1 1, 3, 5 Ta Rb
2 2, 4, 6 R T
a Formulation E*.
b Voltaren 75 mg SR, Batch number: T1339, and Cataflam
25 mg IR, Batch number: Y0086, manufactured by Novartis
Pharma AG, Switzerland.
Formulation and pharmacokinetics of multi-layered matrix tablets 3pressed in RoTab T tablet press (Kg-Pharma, Germany) using
standard concave punches of 10 mm diameter at 15 kN.
2.2.2. Drug layering and coating of the prepared matrix tablets
Layering of tablets with a layer of DP was performed using a
lab scale perforated pan mini coater (Glatt, Pratteln, Switzer-
land). Each of the 450 g batches of tablets was loaded into the
coating pan. The drug layering suspension consisted of 10% w/
w solid content of DP/Opadry II 3:1 in distilled water. The sus-
pension was sprayed using the following conditions: air vol-
ume 25 m3, inlet temperature 78 C, outlet temperature
43 C, spray rate 4 g/min, pump speed 25 rpm, atomization
air 1.5 bar, air pattern 1.5 bar, pan speed 20 rpm and drying
time 15 min. The spraying process continued until achieving
a target tablet mass of approximately 383.3 mg, equivalent to
a drug load of 25 mg DP. An extra outer protective film using
a 20% w/w suspension of Opadry II was applied to add 5% w/
w of the total tablet weight to each tablet to act as a taste
masking and moisture protection layer. The coating conditions
were the same as for the drug layering process except that the
inlet temperature was 60 C and the outlet temperature was
45 C.
2.2.3. Assay for drug content
Drug content uniformity in the tablets was evaluated in accor-
dance with USP guidelines. Ten tablets were taken individu-
ally, weighed, and crushed, and then the drug was extracted
with methanol. The solution was filtered, and samples were
injected into an ACQUITYTM UPLC system (Waters Corp.,
Milford, MA, USA). Briefly, separation was accomplished
using reversed-phase isocratic elution using a 50:50 v/v mixture
of 0.05 M acetate buffer (pH 2.5) and acetonitrile as the mobile
phase at 0.5 ml min1 and an injection volume of 1 ll. The
photodiode array detector was set to acquire two-
dimensional data from 210 to 280 nm; the second channel
was recording at 254 nm. The column temperature was set at
50 C while sample temperature was kept at 10 C. This
method was also used to measure DS content in DS-
containing samples as well as dissolution samples (Elzayat
et al., in press).
To determine the amount of DP alone, analysis for the
amount of potassium present was carried out by flame pho-
tometry against a calibration curve of potassium chloride in
aqueous solution. The exact amount of DP was back calcu-
lated from the flame photometry results.
2.2.4. In-vitro release studies
A USP Type II dissolution apparatus (LOGAN Instrument
Corp., Somerset, NJ), was used to conduct the release studies.
The dissolution medium was 900 ml 0.05 M phosphate buffer
(pH = 7.5) kept at 37 C for 24 h with paddle rotating at
50 rpm. Samples of 5 ml each were collected at predetermined
time intervals and replaced immediately with freshly prepared
dissolution medium. The collected samples were filtered and
analyzed by injection into the UPLC (see Section 2.2.3).
Release studies were conducted in triplicate and the average
value of the cumulative percent of drug release was plotted
against time. The release profiles for the matrix tablets before
coating were compared to those of Voltaren 75 mg. After
drug layering and coating of these tablets, the release profiles
obtained for these tablets were compared to Voltaren 75 mgPlease cite this article in press as: Elzayat, E.M. et al., Formulation and pharmacokin
maceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.004and Cataflam 25 mg when these two commercial products
were placed together in one dissolution vessel.
2.2.5. Modeling of the in-vitro release data
The mechanism of drug release from formulations was eluci-
dated by fitting the data to zero and first order, Higuchi and
Korsmeyer-Peppas models (Elzayat et al., 2016a).
The release efficiency (RE) was calculated from the frac-
tional area under the curve at each time t, as determined using
the trapezoidal rule (Khan, 1975). The mean dissolution times
(MDT) were calculated according to the following equation
(Costa and Sousa Lobo, 2001):
MDT ¼
Pn
j¼1 t^jDMjPn
j¼1  DMj
ð1Þ
where j refers to the number of the sample, n refers to the num-
ber of release time points, t^j refers to the time midway between
t^j1 and t^j, and DMj refers to the extra amount of drug released
between t^j1 and t^j.
The RE and the MDT values were analyzed by one-way
analysis of variance (ANOVA) using SPSS 18 software to
compare their mean values. Fisher’s least significant difference
procedure was used to test for significance and the level of con-
fidence was set at 95%.
The similarity factor among formulations, f2, was deter-
mined (Moore and Flanner, 1996):
f2 ¼ 50 log
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 1
n
 Pn
t¼1ðRt  TtÞ2
h ir  100
0
BB@
1
CCA ð2Þ
where n refers to the number of samples, R refers to the drug
release from the reference material at time t, and T refers to the
drug release from the test sample at time t.
2.2.6. Bioavailability study
2.2.6.1. Administration program and blood sampling. The
administration of the prepared matrix tablets and the mar-
keted product to six dogs was completed according to a two
way crossover design with a one-week washout period between
each treatment phase. Dogs having weight of 12 kg, age of 12–
14 months and sex of 4 females and 2 males, were divided ran-
domly into two groups and allocated to one of the two treat-
ments according to the study design shown in Table 1. Each
dog received the same water and meal prior to treatment. A
single oral dose equivalent to a 100 mg diclofenac dose in
one of the formulations was administered after overnight fast-etics of multi-layered matrix tablets: Biphasic delivery of diclofenac. Saudi Phar-
4 E.M. Elzayat et al.ing for at least 10 h with free access to water. Multiple venous
blood samples for analysis of diclofenac concentrations in
plasma were collected prior to drug administration (0 h) and
at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h post-dose. The volume
of blood taken for determination of diclofenac in plasma was
5 ml. The blood samples were placed in heparinized tubes,
slightly shaken and centrifuged at 3000 rpm for 10 min. The
plasma was then decanted and placed in coded polypropylene
tubes and then stored at 70 C until drug analysis. The pro-
tocol of the study for animal experiments was approved by the
Institutional Animals Ethical Committee of the Department.
2.2.6.2. Plasma sample preparation and drug analysis. One
milliliter of the plasma sample was spiked with 100 ll of
ibuprofen (internal standard: 0.5 mg/ml dissolved in metha-
nol). The sample was vortexed for 30 s, made acidic with
250 ll 0.15 M phosphoric acid, vortexed for another 30 s and
extracted with 5 ml diethyl ether with vortexing for 1 min.
The extract was centrifuged at 3000 rpm for 5 min, and then
3 ml of the supernatant was decanted to a glass tube. The sep-
arated quantity was evaporated to dryness at 50 C and the
remaining residue was dissolved with 1 ml of mobile phase
and vortexed for 1 min. After centrifugation at 15,000 rpm
for 2 min, ten microliters was injected into the UPLC–UV sys-
tem for analysis.
The peak-area ratio of the drug to the peak area of the
internal standard estimated by Masslynx Version 4.1 software
(Waters, USA) allowed quantification of the DS present. The
relationship between concentration and peak area ratio was
linear, with an r2 coefficient of not less than 0.99 within the
range 0.1–30 lg/ml for diclofenac. The lower limit of quantifi-
cation (LLOQ) for diclofenac from 1 ml of plasma was 0.5 lg/
ml. Intra- and inter day accuracy of the method ranged from
97.04% to 107.8% and from 99.2% to 114.7% respectively,
while the intra- and inter-day precision ranged from 0.29%
to 9.3% and from 3.1% to 9.5%, respectively, for concentra-
tions 0.5, 1, 8, 15 and 30 lg/ml. The average absolute analyti-
cal recovery of diclofenac ranged from 93.69% to 107.2%, and
of the internal standard (ibuprofen) was 96.31%.
2.2.6.3. Pharmacokinetic analysis. WinNonlin software (Ver-
sion 4.1, Pharsight Corp., Palo Alto, CA, USA) was used to
determine the pharmacokinetic parameters. Non-
compartmental models (Yamaoka et al., 1978), were employed
for the evaluation of these parameters. The terminal log-linear
portion of the concentration–time curves in plasma was ana-
lyzed by least squares regression analysis to determine the
elimination rate constant and the half-life of the drug. The
trapezoidal method was employed to determine the area under
the concentration–time curve in plasma from zero time to the
last quantifiable concentration (AUC0t) and to infinity
(AUC01). The ratio of Cmax=AUC01 was used as an esti-
mate of the absorption rate constant (Endrenyi et al., 1991).
The area under the moment curves from zero time to the last
quantifiable concentration (AUMC0t) and to infinity
(AUMC01) was also calculated by the trapezoidal method.
The following equation was used to estimate the mean resi-
dence time (MRT):
MRT ¼ AUMC01
AUC01
ð3ÞPlease cite this article in press as: Elzayat, E.M. et al., Formulation and pharmacokin
maceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.004The apparent volume of distribution at steady state (Vss)
was estimated using the following relationship (Perrier and
Mayersohn, 1982):
Vss=F ¼ D AUMC01ðAUC01Þ2
ð4Þ
where F refers to the drug bioavailability of the drug and D
refers to the dose administered. In addition, the oral clearance
of the drug was calculated by the following equation:
CL=F ¼ D
AUC01
ð5Þ2.2.6.4. Statistical analysis. The Statistical Analysis System
software package (SAS Institute, Cary, NC, USA) was
employed. The Student’s t-test for independent samples was
employed to compare the calculated pharmacokinetic parame-
ters between test and reference assuming homoscedasticity. It
is well known that the time to peak plasma concentration
(Tmax) data do not follow a Gaussian distribution; therefore,
the nonparametric Mann–Whitney test was used. The results
were expressed as mean ± SD and comparisons were carried
out at the 0.05 level of significance.
2.2.7. Effect of storage on physical properties and drug release
from the tablets
The multi-layered tablet that demonstrated bioequivalence to
the marketed product was assessed for the effect of long term
and accelerated storage conditions on the physical characters
and release profile, according to International Conference on
Harmonization Guidelines (ICH, 2003). The tablets were
stored in closed containers in stability cabinet (Binder Gmbh,
Tuttlinger, Germany) at 25 ± 2 C and 60 ± 5% relative
humidity (RH) for 12 months and 40 ± 2 C and 75 ± 5%
(RH) for 6 months.3. Results
3.1. Evaluation of the prepared tablets
The characteristics of the core matrix, drug layered and final
coated tablets are listed in Table 2. The core tablets displayed
acceptable weight variation, content uniformity and friability.
Tablets were assessed after drug layering for the coating effi-
ciency by determining the amount of diclofenac potassium
loaded on each tablet. The flame photometry analysis showed
an average DP content of 100.5 ± 3.54%. After the applica-
tion of the final film coat of Opadry II, the average tablet
weight was found to be 400 ± 3.72 mg, hardness 182.1
± 6.33 N, thickness 4.83 ± 0.02 mm and overall diclofenac
content 96.25 ± 1.64%.
3.2. In-vitro drug release
Fig. 1 shows that the release profile of formulation E (core
matrix) and Voltaren 75 mg are similar to each other with
f2 value of 79.2. The release efficiency (RE) and mean
dissolution time (MDT) values were comparable where the
RE was 80.15% and 83.5% and the MDT was 4.81 h andetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. Saudi Phar-
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Figure 1 Comparative release profiles of diclofenac from differ-
ent formulations at pH 7.5: Voltaren 75 mg; Formulation E
(before coat); Voltaren 100 mg; Voltaren 75 mg & Cataflam
25 mg; Formulation E*. Each data point represents the average of
a triplicate study.
Table 2 Physical characterization of biphasic release matrix tablets of diclofenac in the three manufacturing stages (before coat, drug
layered and film coated).
Formulations Formulation E (before coata) DP layeredb Formulation E* (after final film coat)
Drug content (%) (RSD) 94.91 (1.86) 96.25 (1.7) 96.25 (1.7)
Tablet mass (mg) ± SD 351 ± 3.21 385 ± 4.32 400 ± 3.72
Hardness (N) ± SD 105.4 ± 5.17 129.3 ± 13.65 182.1 ± 6.33
Thickness (mm) ± SD 4.46 ± 0.02 4.78 ± 0.02 4.83 ± 0.02
Friabilityc (% loss) ± SD 0.1 ± 0.03 0.02 ± 0.01 0.02 ± 0.01
a Core matrix tablets before drug layering with DP.
b Content calculated based on total diclofenac content.
c Initial mass of 6.5 g.
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Figure 2 Mean diclofenac plasma profiles from a single dose
bioavailability study compared with the reference product (n= 6).
Voltaren SR 75 mg & Cataflam 25 mg; Formulation E*. Each
point represents the mean ± S.E.
Table 3 Pharmacokinetic parameters (mean ± SD) for for-
mulation E* and the reference (Voltaren 75 mg and Cataflam
25 mg) in 6 dogs.
Formulation E* Reference p-value
kel (h
1) 0.121 ± 0.05 0.12 ± 0.05 0.95
t1/2 (h) 6.63 ± 2.69 7.46 ± 5.34 0.74
Tmax (h) 4.83 ± 3.76 4.33 ± 0.82 0.94
Cmax (lg/L) 11.29 ± 6.87 12.97 ± 8.45 0.71
Clast/Cmax 0.13 ± 0.1 0.1 ± 0.12 0.65
AUC0-t (lg h/L) 105.36 ± 83.3 92.87 ± 55.53 0.77
AUC0-1 (lg h/L) 118.12 ± 85.8 104.05 ± 52.05 0.74
AUC ratio 0.88 ± 0.1 0.88 ± 0.19 0.95
Cmax/AUC0-1 (h
1) 0.124 ± 0.1 0.127 ± 0.05 0.91
AUMC0-1 (lg h
2/L) 1357 ± 960 1199 ± 809 0.77
MRT (h) 11.19 ± 4.12 12.12 ± 8.93 0.81
Vss/F (L/kg) 0.89 ± 0.54 1.08 ± 0.94 0.67
CL/F (L kg1 h1) 0.096 ± 0.06 0.094 ± 0.04 0.94
Formulation and pharmacokinetics of multi-layered matrix tablets 54.91 h for formulation E and Voltaren 75 mg; respectively.
Formulation E* (after DP layering and coating) showed an
increased amount of drug released at each time point com-
pared with previous formulations due to the additional drug
load. This was also the case when monitoring the simultaneous
release from the two tablets Voltaren 75 mg and Cataflam
25 mg as the reference product. The release efficiency values
were comparable 86.38% vs 82.72% and the mean dissolution
times were 4.05 h vs 4.52 h for formulation E* and the refer-
ence, respectively.
3.3. Pharmacokinetic study
The plasma concentration–time curves for the two formula-
tions, formulation E* and the reference (Voltaren 75 mg &
Cataflam 25 mg) are shown in Fig. 2. Table 3 lists the phar-
macokinetic parameters of diclofenac in both formulations.
No significant difference between any of the mean values of
the pharmacokinetic parameters calculated for the treatments
was found at a 95% confidence interval (CI). The Cmax values
were 11.29 ± 6.87 and 12.97 ± 8.45 lg/L and the AUC0-24
values were 105.36 ± 83.3 and 92.87 ± 55.53 lg h/L for for-
mulation E* and the reference, respectively. This indicates thatPlease cite this article in press as: Elzayat, E.M. et al., Formulation and pharmacokinetics of multi-layered matrix tablets: Biphasic delivery of diclofenac. Saudi Phar-
maceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.004
Figure 3 Release profiles after stability studies in long term (A) and accelerated (B) conditions for formulation E* according to ICH
guidelines.
6 E.M. Elzayat et al.the rate and extent of absorption were comparable between
these two formulations. These results are in agreement with
the observed in-vitro release data.
3.4. Stability study
The moisture content as well as the rate of moisture uptake is
affected by humidity and temperature and should be consid-
ered. Fig. 3 shows the release profiles for the formulation E*
after storage under long term and accelerated conditions.
Table 4 shows the physical characteristics of formulation E*
and the release profile similarity factor f2 after exposure to
the long term and accelerated conditions as compared to the
initial release profile. There was no significant increase in tablet
mass or hardness. The f2 values for drug release, after long
term and accelerated conditions, ranged from 62 to 71 suggest-
ing similarity to the initial release results.
4. Discussion
4.1. In-vitro drug release
Both formulation E* tablets and the commercially available
formulations (Voltaren SR 75 mg and Cataflam 25 mg)Table 4 Effect of long term and accelerated storage conditions on
similarity factor f2.
Stability status Drug content
(%)
Tablet weight (mg)
± SD
Initial 96.3 (1.7)b 400 ± 3.7
Long term 3 M 96.4 (1.64) 402 ± 3.2
6 M 96.5 (1.64) 400 ± 4.7
12 M 96.8 (1.37) 406 ± 3.6
Accelerated
conditions
3 M 96.5 (1.2) 408 ± 4.3
6 M 96.4 (1.21) 408 ± 4.5
a Amount of tablets weighed equivalent to 6.5 g.
b Values in parentheses are the RSD of the mean.
Please cite this article in press as: Elzayat, E.M. et al., Formulation and pharmacokin
maceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.004exhibited higher initial concentrations when compared to
results of formulation E or Voltaren 75 mg alone due to
the rapid dissolution of the immediate release layer of DP from
formulation E* or the contribution of the rapid disintegration
followed by dissolution of diclofenac by the Cataflam 25 mg
tablet. The remainder of the drug is released over a 16 h per-
iod; however, the core matrix did not lose its integrity even
after 24 h. The drug release from formulation E* reached
42% in 1 h, which suggests that the pharmacologic effect can
be attained rapidly. Analysis of drug release data revealed that
release from formulation E* or the reference material occurred
by diffusion (Higuchi model fit with r2 = 0.99) where the
release of diclofenac was dependent on the square root of time.
The Korsmeyer-Peppas exponent (n) was 0.34 and 0.405 for
formulation E* and the reference, respectively after fitting
the dissolution profiles into the exponential equations. It can
be inferred from n< 0.45 that diffusion is the dominating
mechanism in the release process from these matrix type for-
mulations (Su et al., 2003). After exposure of the inner matrix
to the aqueous medium, solvent penetrates into the voids
between macromolecular chains of Eudragit RL more easily
allowing solvation of the polymer chains. This might suggest
polymer relaxation as a result of increased polymer dimensions
due to the hydrostatic pressure build up by the entered solvent
(Apu et al., 2009). The similarity factor (f2) value was found tothe physical properties of formulation E* (mean ± SD) and the
Hardness (N)
± SD
Thickness (mm)
± SD
Friabilitya
(% loss)
f2
182 ± 6.3 4.83 ± 0.02 0.02 N/A
166 ± 7.2 4.87 ± 0.02 0.02 71.74
167 ± 6.6 4.87 ± 0.02 0.03 64.14
189 ± 4.9 4.86 ± 0.03 0.01 62.02
194 ± 6.6 4.92 ± 0.01 0.01 66.2
192 ± 5.8 4.92 ± 0.01 0.01 63.31
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from the two formulations.
4.2. Pharmacokinetic study
The bioavailability study presents strong evidence for bioe-
quivalence between the test and comparator formulations.
Being a highly permeable drug, diclofenac is found to be
absorbed throughout the gastrointestinal tract (Gleiter et al.,
1985). After dosing of the two formulations, the plasma con-
centration of diclofenac was easily detectable in the blood after
30 min from each of the formulations. This corresponded well
with the observed pulse effect of drug release that occurred due
to the fast dissolution of DP layer in formulation E* and the
rapid drug release of DP from Cataflam 25 mg. The in-vivo
profiles can be explained on the basis of the three main stages.
The first stage takes place from 0 to 2 h where the extent and
rate of absorption of formulation E* were higher than those of
the reference. This can be attributed to the rapid dissolution of
the immediate release coat containing DP. On the other hand,
the Cataflam 25 mg tablet tends to disintegrate first and then
dissolution begins, and this decreased the absorption rate rel-
ative to formulation E*. The second stage is from 2 to 7 h at
which point the drug reached the small intestine which has a
high effective surface area that facilitates absorption. Even
though diclofenac solubility is higher, with greater extent of
absorption, in the small intestine than in the stomach, the
absorption rate in case of formulation E* is controlled by the
core matrix which, according to Fig. 1, releases drug at a
slower rate than did the outermost coat with its DP. And that
is what is reflected in the 2–7 h time frame in Fig. 2. Although
the release from the core of Formulation E* is slightly slower
than observed with the rate provided by the reference combi-
nation of the commercial products, there is still no statistical
difference between the two formulations at each point of the
drug release during this stage which may be attributed to the
wide scatter in the reference data. In the third stage from 8
to 24 h, a higher level of the drug in the blood was detected
from formulation E* than the reference combination where
the drug in formulation E* continued to be released from the
tablets. Formulation E*, hence, keeps an elevated diclofenac
concentration in the plasma for a longer time which is good
for the patient.
4.3. Stability study
The drug release and the physical characteristics of the tablets
remained unchanged after storage for 1 year under long term
conditions and 6 months at accelerated conditions suggesting
that DS is stable in the multi-layered tablets. Noticeably, there
was an insignificant decrease in the drug release after 10 h in
both long and accelerated conditions. This effect can be linked
with the slight increase in hardness of the tablets. The long
exposure of the tablets to elevated humidity/temperature might
promote fusion of the polymer particles due to increased
mobility with possible redistribution of the pores within the
matrix system (Grund et al., 2014). This resulted in a small
retardation in the drug release in accordance with similar find-
ings that have been reported previously (Grund et al., 2014).Please cite this article in press as: Elzayat, E.M. et al., Formulation and pharmacokin
maceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.10.004However, the overall assessment of the release profile indicates
stability of the tablets according to ICH guidelines.
5. Conclusion
Modification of Eudragit-based matrix systems made it possi-
ble to achieve biphasic drug release patterns. A first pulse was
obtained by incorporation of a percentage of the drug in an
outer immediate release layer applied onto a release control-
ling matrix which would provide the sustained pharmacologic
effect. The clinical significance of such formulations would be
profound with patients suffering from acute or long lasting
pains. Based on its in-vitro, in-vivo and stability profiles of for-
mulation E*, it is a system that can accomplish both immediate
and sustained release of diclofenac for extended pain relief.
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